# HIV SURVEILLANCE REPORT – 2018 UPDATE

Special Preventive Programme
Centre for Health Protection
Department of Health
Hong Kong Special Administrative Region
December 2019

### This report is produced and published by:

Surveillance Team
Special Preventive Programme
Centre for Health Protection
Department of Health
Hong Kong Special Administrative Region

### Team members:

Dr Kenny CHAN Dr Billy CH HO Dr Sheldon FUNG Mr Kenny MAK Ms Rita LUI

### **Correspondence:**

Special Preventive Programme c/o 2/F, Wang Tau Hom Jockey Club Clinic 200 Junction Road East Kowloon, Hong Kong

Tel: (852) 3143 7225 Fax: (852) 2780 9580

Website: http://www.aids.gov.hk

E-mail: aids@dh.gov.hk

## **CONTENTS**

Co	NTENTS	3
PRI	EFACE	5
Acı	KNOWLEDGEMENTS	6
Аві	BREVIATION	7
1.	SUMMARY REVIEW  Background  HIV/AIDS reporting system  Discussion	8 9 23
2	TABULATED RESULTS OF HIV/AIDS REPORTING	-
2.	System description	<b>25</b> 25
	Box 2.1 Annual and cumulative reports of HIV/AIDS cases	27
	Box 2.2 Source of reporting of HIV/AIDS cases	28
	Box 2.3 Ethnicity & gender of reported HIV/AIDS cases	30
	Box 2.4 Age distribution of reported HIV/AIDS cases	32
	Box 2.5 Exposure category of reported HIV/AIDS case	38
	Box 2.6 Reported HIV/AIDS cases in people who inject drugs	40
	Box 2.7 Reported sexually acquired HIV/AIDS cases	42
	Box 2.8 Profile of primary AIDS defining illnesses (ADI)	45
3.	TABULATED RESULTS OF HIV PREVALENCE SURVEYS	46
	System description	46
	Box 3.1 HIV prevalence in blood donors at Hong Kong Red Cross Blood Transfus	sion
	Service	48
	Box 3.2 HIV prevalence in clients attending Social Hygiene Services, from	
	voluntary blood testing	50
	Box 3.3 HIV prevalence in drug users attending methadone clinics	51
	Box 3.4 HIV prevalence in drug users attending inpatient drug treatment centre	
	institutions, from unlinked anonymous screening	52
	Box 3.5 HIV prevalence in newly admitted prisoners from unlinked anonymous	
	screening	53
	Box 3.6 HIV prevalence in patients attending government TB & Chest Clinics, fr voluntary blood testing	54
	Box 3.7 HIV prevalence among antenatal women from Universal Antenatal HIV	_
	Antibody Testing Programme	55
	Box 3.8 HIV prevalence among MSM tested by AIDS Concern	56
	Box 3.9 HIV prevalence among MSM – PRiSM, HARIS	57
	Box 3.10 HIV prevalence among Female Sex Workers – CRiSP, HARIS	58

4.	TABULATED RESULTS OF STATISTICS ON SEXUALLY TRANSMITTED INFECTIONS (STI)  System description	59 59
	Box 4.1 Total number of STI newly reported by individual Social Hygiene Clinic	60
	Box 4.2 Annual newly reported STIs in Social Hygiene Clinics	62
	Box 4.3 Syphilis newly reported by Social Hygiene Clinics	63
	Box 4.4 Sexually acquired HIV infection in Hong Kong	64
	Box 4.5 Syndromic presentations of STI from Behavioural Survey of Social Hygie	ene
	Service	65
5.	TABULATED RESULTS ON BEHAVIOURAL MONITORING	66
	System description	66
	Box 5.1 Median number of sex partners in the previous year among adult	
	heterosexual men / MSM attending AIDS Counselling and Testing Service	се
	(ACTS)	68
	Box 5.2 Recent history of commercial / casual sex among adult heterosexual	
	men	69
	Box 5.3 Condom use with regular partners among adult heterosexual men	70
	Box 5.4 Condom use with commercial / casual partners among adult heterosexu	
	men	72
	Box 5.5 Condom use among Men have Sex with Men (MSM)	74
	Box 5.6 Proportion of current injectors	76
	Box 5.7 Proportion of current needle-sharers	77
6.	TABULATED RESULTS OF HIV-1 GENOTYPING STUDIES	78
	System description	78
	Box 6.1 Proportion of reports with subtypes by year in Hong Kong	79
	Box 6.2 Distribution of HIV-1 subtypes	80
	Box 6.3 Trend in the common HIV-1 subtypes in Hong Kong	81
	Box 6.4 Trend in HIV-1 subtype CRF01_AE in Hong Kong	82
	Box 6.5 Trend in HIV-1 subtype B in Hong Kong	85
	Box 6.6 Trend in HIV-1 subtype C in Hong Kong	88
	Box 6.7 Prevalence of intermediate or high level drug resistance related mutation	on
	among newly diagnosed HIV patients	91
AP	PENDIX I: HIV/AIDS REPORT FORM (DH2293)	92
<b>A</b> P	PENDIX II: CLASSIFICATION SYSTEM FOR HIV INFECTION AND SURVEILLANCE CASE	
	DEFINITION FOR AIDS IN ADOLESCENTS AND ADULTS IN HONG KONG.	93
AP	PENDIX III: CONDOM DISTRIBUTION FOR THE PREVENTION OF HIV AND STI BY	
	DEPARTMENT OF HEALTH	94

#### **PREFACE**

The number of reported HIV infections remained high in 2018 at 624. Sexual transmission was the major route of HIV transmission in Hong Kong thus far, while transmission from other routes including drug injection had been staying at a relatively low level. Overall, Hong Kong continues to have a low prevalence of HIV infection in the general population.

Similar to many developed countries, Hong Kong is facing the ongoing challenge of a high level of HIV infection in the men who have sex with men (MSM) community in recent years. Besides their prominence in the number of reported cases, MSM was also shown to have the highest HIV prevalence among all at risk populations. And despite a relatively low prevalence among people who inject drugs (PWID, previously known as injecting drug users (IDU)), one should not be complacent as infection could surge quickly in this population given the opportunities.

With the expansion of community-based HIV voluntary testing services, non-governmental organisations have been playing an increasingly important role in the understanding of the local HIV epidemiology especially among the at-risk populations of MSM, PWID and female sex workers. Many non-governmental organisations have participated in HIV prevalence & behavioural surveys in different at-risk populations through their service networks.

This annual surveillance report is an initiative of Special Preventive Programme, Centre for Health Protection, Department of Health. The report aims to provide strategic information to facilitate planning of services and intervention activities for the prevention, care and control of HIV/AIDS. Following a commentary, data collected from the five main components of our surveillance programme (the HIV/AIDS voluntary reporting system, HIV prevalence surveys, sexually transmitted infections caseload statistics, behavioural studies and HIV-1 genotyping studies) were presented as tables and graphs. Findings of the risk behavioural surveys such as the HIV and AIDS Response Indicator Survey (HARiS) and other studies were also included in this report.

Electronic copy of this report is accessible in our website <a href="http://www.aids.gov.hk">http://www.aids.gov.hk</a>. Moreover, the quarterly bulletins, factsheets on yearly situation and specific surveys, and other information relating to HIV surveillance and epidemiology are also available in the website. Your comments and suggestions are always welcome.

Surveillance Team
Special Preventive Programme
Centre for Health Protection
Department of Health
December 2019

### **A**CKNOWLEDGEMENTS

This report is only achievable with the concerted efforts contributed by many different stakeholders. First and foremost, we would like to thank our colleagues of the Social Hygiene Service, the Narcotics and Drug Administration Unit, Tuberculosis & Chest Service, Family Health Service, Surveillance and Epidemiology Branch and the Virology Division of Public Health Laboratory Services Branch who have provided the necessary data and support over the years. For data collected in the prison setting, we are indebted to the staff of the Correctional Services Department for their invaluable assistance in carrying out HIV prevalence surveys on a regular basis.

Secondly, special thanks are due to the many agencies that have helped collect and update the relevant statistics included in this report. They included the Hong Kong Red Cross Blood Transfusion Service, the Society for the Aid and Rehabilitation of Drug Abusers, AIDS Concern, the Narcotics Division of the Security Bureau, the Department of Microbiology of the University of Hong Kong, the Jockey Club School of Public Health and Primary Care of the Chinese University of Hong Kong, many of our local AIDS and non-AIDS non-governmental organisations and various public hospitals / clinics, in particular the Queen Elizabeth Hospital, Prince of Wales Hospital and Princess Margaret Hospital. We also take this opportunity to thank all doctors, other health care professionals and related workers who have contributed to HIV/AIDS reporting and other surveillance components.

Finally, we must thank the usual excellent support from the SPP staff in collecting, collating and analysing the information as well as the editing and production of this report.

#### **ABBREVIATION**

ACTS AIDS Counselling and Testing Service

ADI AIDS Defining Illness

AIDS Acquired Immune Deficiency Syndrome

AC AIDS Concern

AIMSS Asia Internet MSM Sex Survey

CDC Centers for Disease Control and Prevention

CRISP Community based Risk behavioural and SeroPrevalence survey for

female sex workers

CD4 Cluster of Differentiation (CD) 4 molecule

CHOICE Community Health Organisation for Intervention, Care and

**Empowerment** 

CRDA Central Registry of Drug Abuse
CHP Centre for Health Protection
CRF Circulating Recombinant Form

DH Department of Health

DRS-M Drug Rehabilitation Services – Methadone clinics

DRS-S Drug Rehabilitation Services – Shek Kwu Chau Treatment and

Rehabilitation Centre

ELISA Enzyme-linked Immunosorbent Assay

FSW Female Sex Worker

HE Heterosexual

HAART Highly Active Antiretroviral Therapy
HARIS HIV and AIDS Response Indicator Survey

HIV Human Immunodeficiency Virus ITC Integrated Treatment Centre

MUT Methadone Universal HIV Antibody (Urine) Testing

MSM Men who have Sex with Men
NSGI Non-specific Genital Infection
NGU Non-gonococcal Urethritis
PCP Pneumocystis Pneumonia
PCR Polymerase Chain Reaction

PRISM HIV Prevalence and Risk behavioural Survey of Men who have sex with

men

PWID People who inject drugs

SARDA The Society for the Aid and Rehabilitation of Drug Abusers
SKC Shek Kwu Chau Treatment and Rehabilitation Centre

STI Sexually Transmitted Infection SPP Special Preventive Programme

SHS Social Hygiene Service SAS Street Addict Survey

TB Tuberculosis ul microlitre

### 1. SUMMARY REVIEW

### **Background**

- 1. The HIV surveillance system in Hong Kong comprises 5 main programmes to provide a detailed description of the local HIV/AIDS situation. They are (a) voluntary HIV/AIDS case-based reporting; (b) HIV prevalence surveys; (c) sexually transmitted infections (STI) caseload statistics; (d) behavioural studies; and (e) HIV-1 genotyping studies. All data are collected, analysed and disseminated regularly by the surveillance team of Special Preventive Programme (SPP), Centre for Health Protection (CHP), Department of Health (DH). At present, the latest HIV/AIDS statistics are released at quarterly intervals at press media briefings and in electronic format (http://www.aids.gov.hk). Data from various sources are compiled annually and released in this report.
- 2. The following paragraphs highlight the main findings from HIV/AIDS surveillance activities undertaken in 2018 and before. Please refer to the following pages for details of the programmes.

### **HIV/AIDS** reporting system

- Department of Health implemented a voluntary anonymous casebased HIV/AIDS reporting system since 1984, which receives reports from doctors, AIDS service organisations and laboratories. They report newly diagnosed HIV cases by a standard form (DH2293) which was last revised in April 2019. Before 2006, only cases confirmed HIV antibody positive by Western Blot were counted as HIV infection for cases aged above 18 months. Since the 4th quarter of 2006, cases with PCR positive result and clinical or laboratory indication of recent infection have also been counted as confirmed HIV infection in the reporting system.
- 4. In 2018, DH received 624 HIV and 139 AIDS reports (Box 2.1). The number of reported HIV cases decreased by 8% to 624 in 2018 compared to 681 in 2017 and by

### HIV Surveillance at a glance (2018)

- 624 HIV reports and 139 AIDS reports
- Sex: 84.9% male
- Ethnicity: 72.1% Chinese
- Age: Median 36
- Risks:
  - 59.6% Homosexual/bisexual contact
  - 23.1% Heterosexual contact
  - 0.5% People who inject drugs
  - 16.8% Undetermined
- CD4 at reporting: Median 263/ul
- HIV-1 subtypes: commonest is CRF01\_AE, followed by B
- Commonest primary AIDS defining illness: PCP, followed by TB
- HIV prevalence
  - Blood donors: <0.01%</li>
     Antenatal women: 0.01%
     STI clinic attendees: 0.38%
  - Methadone clinic attendees: 0.91%


around 14% compared to the record high of 725 cases recorded in 2015. This brought the cumulative total to 9715 and 1996 for HIV and AIDS reports respectively. Public hospitals / clinics / laboratories were still the commonest source of HIV reports in 2018, which accounted for 44.9% of all. Private hospitals / clinics / laboratories and Social Hygiene Clinics were other common sources of HIV reports, accounting for 15.7% and 14.4% respectively. (Box 2.2). The annual number of reported AIDS cases in 2018 is 139, a record high number of yearly AIDS cases recorded since 1985.

5. In 2018, around 84.9% of reported HIV cases were male. The male-to-female ratio was 5.6:1 in 2018, which had decreased as compared to 6.7:1 in 2017. About 72.1% of reported cases were Chinese. Asian non-Chinese accounted for 11.2% of reports. (Box 2.3) The median age of reported HIV cases was 36 (Box 2.4) and 20-29 was the commonest age group in male cases and 40-49 in female cases. Around 83% of reported HIV cases were reported to have acquired the virus through sexual transmission in 2018, including homosexual (50%), heterosexual (23%), and bisexual exposure (9%). People who inject drugs accounted for 0.5% of reported HIV infections. There was no reported case of HIV transmission via blood/blood product transmission or the perinatal route in 2018. The suspected routes of transmission were undetermined in around 17% of cases. This means that after excluding those with undetermined exposure category, sexual transmission accounted for about 99% among HIV reports with defined risks. (Box 2.5(a))

# Concerning was the predominance of infections among men who have sex with men (MSM)


- 6. Similar to previous few years, sexual contact including both heterosexual and homosexual / bisexual, remained the commonest route of HIV transmission in Hong Kong in 2018, which accounted for 83% of reported HIV cases. In the 1980s and early 1990s, the early years of HIV/AIDS epidemic in Hong Kong, more cases in MSM, who had homosexual or bisexual contacts, were reported as compared with heterosexual contact. In 1993, the trend began to reverse, with heterosexual transmission overtaking homosexual / bisexual transmission. Since 2004, a rising trend in MSM has been observed again. In 2005, MSM infections began to outnumber those by heterosexual transmission. In 2018, there were 372 MSM cases (72%) identified out of 519 cases with defined risks. (Box 2.5(a))
- 7. The high weighting of MSM among male HIV cases remained obvious. 70.2% of all male HIV reports in 2018 acquired the virus through homosexual or bisexual contact. Heterosexual contact in male cases accounted for 14.0%, whereas the routes of transmission were undetermined in another 15.3% of the male cases. The ratio of heterosexual men against MSM gradually dropped from its peak of 4.2:1 in 1998 to 0.8: 1 in 2005 and was 0.2:1 in 2018. (Box 1.1 and Box 2.7(c)) A similar trend of increasing AIDS cases among MSM was observed; the ratio of heterosexual men against MSM decreased dramatically from 23.5:1 in 2000 to 0.3:1 in 2018.

Box 1.1 The number of MSM cases has exceeded that of heterosexual men in the reporting system since 2005





8. In 2018, the majority of the MSM cases were Chinese (88.7%). The number of reported Chinese MSM cases remained high in recent years. (Box 1.2) In 2018, the median age of MSM cases at reporting was 32, which was much lower than that of heterosexual male cases at 44. The median age of HIV infected MSM population has shown a decreasing trend in the past few years from 37 in 2010 to 32 in 2018. (Box 1.3) In 2018, the age group of 20-29 was the largest, accounting for 40.1% of reported MSM cases, followed by that of 30-39 (28.5%) and that of 40-49 (16.4%). (Box 1.4) Reported data since 2009 showed that a relatively high proportion of MSM infections occurred in Hong Kong, as compared to a lower proportion in heterosexual men. In 2018, 76.3% of MSM infection reports cited Hong Kong as the suspected place of infection, while only 59.5% of heterosexual male infection was locally acquired. (Box 1.5)

Box 1.2 Ethnicity breakdown of HIV-infected MSM cases (2009-2018)



Box 1.3 Median HIV reporting age of HIV-infected MSM cases, heterosexual men and heterosexual women (2009-2018)






Box 1.4 Age breakdown of HIV-infected MSM cases (2009 - 2018)

Year

Box 1.5 Suspected location of HIV infection (2009 – 2018)



# HIV prevalence among men who have sex with men was significantly higher than other at-risk populations

9. The fourth round of HIV Prevalence and Risk behavioural Survey of Men who have sex with men in Hong Kong (PRiSM) conducted in 2017 showed an HIV prevalence of 6.54% among local sexually active MSM, showing that Hong Kong is an area of concentrated HIV epidemic according to the World Health Organization's definition. This figure was higher than the findings from the second HIV and AIDS Response Indicator Survey (HARiS) conducted in 2014 (5.85%). (Box 1.6 and Box 3.9) However, due to difference in methodology and recruitment strategies between PRiSM (community-based) and HARiS (venue-based), the rates could not be directly compared. Nevertheless, it is clear that the prevalence among MSM is significantly higher than other at-risk populations such as female sex workers (Box 3.10) and drug users (Box 3.3 and Box 3.4).

10. AIDS Concern's voluntary HIV testing service targeting MSM provides another data source to estimate the HIV prevalence in the local MSM community, despite the fact that sampling bias could not be excluded. It showed a prevalence of 1.28% in 2018, compared to 1.84% in 2017. (Box 3.8)

# Condom use and HIV testing among men who have sex with men showed a decreasing trend

- 11. In PRiSM 2017, the rate of consistent condom use (defined as always using a condom for anal sex in the preceding 6 months) reported by MSM respondents were 52.1% for receptive sex and 52.2% for insertive sex. The condom use rate in the last anal sex with emotional relationship partner, regular sex partner, non-regular sex partner and commercial male sex worker were 62.3%, 75.6%, 85.5% and 81.6% respectively. HARiS 2018 for MSM showed that the condom use rate in the last anal sex with emotional relationship partner, regular sex partner, non-regular sex partner and commercial male sex partner were 60.2%, 67.4%, 78.8% and 78.6% respectively. Except for emotional relationship partner, all of these figures were lower than those in HARiS 2016. (Box 1.6(a)) Effort to promote safer sex with all types of partners, irrespective of the relationship, should be enhanced among the MSM community.
- 12. In HARIS 2018, 83.0% of the respondents had ever had HIV testing and 64.5% of respondents had their recent tests performed in the previous year. The rates were increased over those in HARIS 2016 (ever HIV testing rate, 75.8% and HIV testing rate in the previous year, 58.5%). Health promotion of regular HIV testing should be maintained among MSM.

Box 1.6(a) Results of PRiSM (MSM), 2011 and 2017, and HARIS (MSM), 2013-2016, 2018

Results	PRISM	1 2011	HARIS	HARIS	HARIS	HARIS	PRISM	HARIS
			2013	2014	2015	2015 2016		2018
	Venue-	Interne-	Venue-b	ased, centi	re-based a	and	Internet-	Venue-
	based based internet-based							based,
								centre-
								based
								and
								internet-
								based
Sample Size	816	180	853	564	1091	1989	4133	2051
Adjusted HIV prevalence	4.08%	3.3%	/	5.85%	/	/	6.54%	/
(PRiSM)/HIV	(95% CI	(95% CI		(95% CI			(95% CI	
prevalence	3.44-	1.54-		4.28-			5.66-	
(HARIS)	4.85%)	7.08)		8.1)			7.42%)	
Condom use in ERP*	last anal so	ex with:	63.7%	65%	65.7%	59.9%	62.3%	60.2%
RSP*	61.9%	60.0%	76.7%	70.3%	73.6%	70.5%	75.6%	67.4%
NRSP*	82.7%	81.4%	79.5%	80.6%	81.1%	79.9%	85.5%	78.8%
141.51	(in HK)	(in HK)	73.370	00.070	01.170	73.370	03.370	70.070
	81.2%	79.2%						
	(outside	(outside						
	HK)	HK)						
CSP*	/	/	69.9%	89.1%	96.1%	89.1%	81.6%	78.6%
							(commercial sex worker)	
*ERP: Emotion	al Relations	ship Partne	r	*RSP:	Regular S	ex Partne	r	1
*NRSP: Non-re	egular Sex P	artner		*CSP:	Commerc	cial Sex Pa	rtner	

	PRiSM	1 2011	HARIS 2013	HARIS 2014	HARIS 2015	HARIS 2016	PRISM 2017	HARIS 2018
HIV testing								
Ever tested for HIV	67%	63%	73.7%	78.5%	77.5%	75.8%	79.4%	83.0%
HIV test within the past 12 months	40%	41%	57.0%	62.3%	60.8%	58.5%	52.6%	64.5%

- 13. According to the survey conducted among the clients of the DH's AIDS Counselling and Testing Service (ACTS), the median number of casual sex partners in previous year among MSM was consistently higher than heterosexual men, being 3 in 2018. (Box 5.1) The consistent condom use rate among MSM with regular partners and casual partners showed a decrease in 2018, at 39.6% and 41.7% respectively, as compared with the rate of 44.2% and 52.1% in 2017. (Box 5.5(a)) Similarly, the rate of condom use at last anal sex with regular partners and with casual partners showed a decrease (49.1% and 54.7% respectively) in 2018, as compared with 62.8% and 70.3% in 2017 respectively (Box 5.5(b)).
- 14. Additional behavioural data from MSM attending AIDS Concern's testing service showed that the rate of consistent condom use for boyfriend, regular sex partners and casual sex partners was relatively stable in 2018 at 38.5%, 46% and 59.9% respectively. (Box 5.5(a)). Consistent condom use was consistently lower for sexual partners with closer relationship.

#### Male-to-female transgender population

- 15. Male-to-female transgender has been a neglected and hard-to-reach community; yet various overseas studies have shown that their HIV prevalence can be high. To better study the situation in Hong Kong, male-to-female (m-t-f) transgender persons were included as one of the major at-risk populations in HARiS for the first time in 2014. In the survey, it was found that the overall HIV prevalence was 18.6% in m-t-f transgender. In PRiSM 2017, of the 104 participants recruited, 56 submitted urine specimens for HIV antibody testing. The overall HIV prevalence for sexually active m-t-f transgender was found to be 5.11%. (Box 1.6(b))
- 16. M-t-f transgender is a hard-to-reach population. Both the sample size and mix of ethnicity in surveys have varied. For example, in HARiS 2014, of the 59 m-t-f transgender persons recruited, only 69.5% of the participants were Chinese and a considerable proportion were non-Chinese (Filipino 16.9% and Thai 11.9%) while in PRiSM 2017 (N=104), 93.3% were Chinese. Due to the small sample size and different recruitment strategies between surveys, the rates should be interpreted cautiously. Overall, the condom use rate and HIV testing rate was unsatisfactory. Education on safer sex practices, including consistent and correct use of condom, and promotion of HIV testing should be reinforced.

Box 1.6(b) Results of HARIS (TG) 2014 - 2016, 2018, and PRISM (TG) 2017

Results	HARIS 2014	HARIS 2015	HARIS 2016	PRISM 2017	HARIS 2018
Sample Size	59	66	87	104	41
HIV prevalence	18.6%	/	/	5.11%	
	(95% CI 9.74-			(95% CI 0.06-	
	32.62)			10.16%)	
Condom use in last a	nal sex with:				
ESP*	75.8%	82.1%	55.6%	55.6%	58.3%
RSP*	90.0%	85.7%	63.0%	58.5%	76.5%
NRSP*	76.9%	91.9%	84.4%	68.3%	78.3%
CSP*	76.3%	93.8%	96.8%	60.0% (commercial sex worker)	90.0%
*ESP: Emotional Rela	ıtionship Partner		*RSP: Regular	Sex Partner	
*NRSP: Non-regular S	•		_	rcial Sex Partner	
HIV testing					
Ever test for HIV	72.9%	78.8%	65.5%	72.1%	90.2%
HIV test within past year	50.8%	60.6%	57.5%	41.3%	65.9%

### The proportion of heterosexual cases remained stable

17. In 2018 there was a total of 144 heterosexual cases reported, which accounted for about one-fourth of all reported HIV cases. (Box 2.5(a)) The proportion of heterosexual cases among all reported HIV cases dropped from its peak of 71% in 1998 to 33% in 2008 and was 23.1% in 2018. In recent years, however, the female heterosexual cases rose slightly faster than the male cases, resulting in a gradual increase of female to male ratio for heterosexual cases from 0.5:1 in 2004 to 0.95:1 in 2018. The median age of heterosexual cases in 2018 was 41.5 for female and 44 for male. In 2018, heterosexual male cases were mainly Chinese (67.6%) whereas Chinese accounted for 34.3% only for female heterosexual cases.

- 18. STI caseload statistics from Social Hygiene Clinics is an important component of the local HIV surveillance programme as the presence of STI is an indicator of high risk sexual behaviours. In 2018, 14.4% of reported cases were referred from Social Hygiene Clinics. The consistent condom use rate among heterosexual men attending Social Hygiene Clinics with commercial / casual partners in the past 3 months in 2018 was 51.5%, comparable to the rates in previous years. (Box 5.4(a)) Moreover, more than one third of the STI cases were asymptomatic, which may delay the diagnosis and the link to appropriate medical care. (Box 4.5) The HIV prevalence of Social Hygiene Clinic attendees has remained stable in recent few years, being 0.379% in 2018. (Box 3.2) The total number of STI cases in Social Hygiene Clinics also remained relatively stable in the past few years, with an aggregate of 11,667 cases in 2018. (Box 4.1 and Box 4.2)
- 19. The level of consistent condom use observed among those attending AIDS Counseling and Testing Service (ACTS) decreased slightly from 74% in 2017 to 71.4% in 2018 for commercial partners and from 62.3% in 2017 to 58.4% in 2018 for commercial / causal partners. (Box 5.4(a))

# New HIV infection among drug users remained low but significant risk behaviours were reported

- 20. In 2018, the reporting system recorded 3 cases of HIV transmission in PWID, which accounted for 0.5% of all reported cases. Historically, this number decreased from the peak of 58 cases in 2006 to less than 10 cases in 2012 and has since remained at a low level. (Box 2.5(a)) All cases in 2018 were male, including one Chinese, one non-Chinese Asian and one of white ethnicity. (Box 2.6(a)) The median age was 50. Two out of the three PWID cases were reported from Public hospitals / clinics / laboratories.
- 21. The Methadone Universal HIV Antibody (Urine) Testing Programme (MUT) has replaced the past unlinked anonymous screening (UAS) in methadone clinics since its launch in 2004. It aims to strengthen HIV surveillance among drug users as well as diagnosis and subsequent care of the HIV infected clinic attendees. Among the 7424 methadone clinic attendees in 2018, 4715 clients have been tested for HIV, giving an overall HIV testing coverage rate of 63.5%. A total of 43 clients were found to be positive for HIV, giving an overall HIV prevalence of 0.91% among methadone clinic attendees in 2018. (Box 3.3)
- 22. The proportion of drug users who were currently injecting drugs ranged from 24% to 83% across different surveys in 2018. (Box 5.6) In addition, various surveys showed that 0% to 12.1 % of them were practising needle sharing, which put them at risk of HIV. (Box 5.7) Therefore, the potential risk of HIV outbreak among drug users cannot be neglected, despite the fact that the number of reported cases has remained small in recent years.

#### No case of transmission via blood/blood product transfusion reported

23. In 2018, there was no reported case of HIV infection via contaminated blood or blood product transfusion. The HIV prevalence of new blood donors at Hong Kong Red Cross Blood Transfusion Service remained at a low level of 0.010 % in 2018 (Box 3.1(b)).


### No case of perinatal transmission reported

24. In 2018, there were no reported case of HIV infection via perinatal transmission. Since the launch of the Universal Antenatal HIV Testing in September 2001, around 50,000 pregnant women attending public antenatal services were tested for HIV every year. The coverage of the programme remained at a high level, all cases (45,530) were tested in 2018 and the prevalence of HIV infection in pregnant women was found to be stable over the years (0.01% in 2018) (Box 3.7).


### Reconstruction of risk factor for cases without reported route of transmission

- 25. As the HIV/AIDS case-based reporting system in Hong Kong is voluntary and anonymous, the completeness of the local surveillance database depends heavily on the percentage of cases with the report form DH2293 received from attending doctors / NGOs. Incomplete data without a reported risk factor may skew the local epidemic picture. In 2018, 17% of the infected cases did not have a suspected route of transmission reported, as compared to around 14% in 2017. (Box 2.5(a)) A systematic reconstruction method proposed by Dr. Tim Brown, Senior Fellow of the East-West Centre, Honolulu has been used since 2010 to factor in the weightings of undetermined risk cases, to assess the risk for local transmission and to plan and guide appropriate preventive actions.
- 26. Reconstruction was carried out by assigning one suitable route of transmission to the undetermined cases. After the analysis of the features of these cases with undetermined risk factor and the prevailing epidemic, it was assessed that all female infections shall be assumed to be acquired through heterosexual transmission, unless there is clear indication suggesting otherwise. As for the male cases of undetermined risk factor, it was assessed that they shall be assumed to be either heterosexual contact or homosexual contacts as the risk factor of transmission, subject to the observed ratio in the prevailing year between heterosexual and homosexual contact, providing there is no other indication suggesting otherwise.
- 27. The original 10-year data on risk factors from 2009 to 2018 was used for the reconstruction (Box 1.7(a)). After the reconstruction, the cases of MSM showed a marked increase up to 2017, while the change in heterosexual male appeared to be relatively modest. (Box 1.7 (b and c)) Although this method might have oversimplified the complex local epidemic, it provides one possible solution to fill the gap in the HIV surveillance system information. Measures to promote the return rate of report forms from doctors have also been implemented in the past few years.


Box 1.7(a) HIV reports before risk factor reconstruction (2009-2018)



Box 1.7(b) HIV reports after risk factor reconstruction (2009-2018)



Box 1.7(c) HIV reports before and after risk factor reconstruction in MSM, heterosexual male and heterosexual female cases (2009-2018)



### Regular HIV testing before diagnosis was still not a norm in Hong Kong

28. The HIV/AIDS Report Form (DH2293) was revised in 2010 with one data field added to capture the previously negative HIV result among the newly diagnosed cases. The data helps to inform the epidemiology of those cases who were recently infected. Among the 624 cases reported in 2018, data of the HIV/AIDS Report Form was available in 538 cases, of which only 181 cases (33.6%) had the data on previously negative HIV results, which implied regular testing among HIV patients before their diagnoses was uncommon. Among those 181 cases, 70 (38.7%) had previously negative HIV results within one year of the HIV diagnosis, suggesting recent infection within 1 year of the HIV diagnosis. For those whose last negative HIV results were beyond one year of HIV diagnosis, however, it was not possible to judge whether they were recently HIV seroconverted or not, as the observation was limited by the infrequent testing behaviour.

# <u>Pneumocystis</u> Pneumonia and Tuberculosis remained the two commonest primary <u>AIDS Defining Illnesses</u>

29. Since the introduction of highly active antiretroviral therapy (HAART) in Hong Kong around 1997, the annual number of reported AIDS cases has been dropping since then and then remained at a relatively stable level of around 80 to 110 cases per year in the past decade. Of note, as many as 139 AIDS cases were reported in 2018. This compared with 91 cases in 2017 (Box 2.5(b)). The vast majority (91.4%) of the AIDS reports in 2018 had their AIDS diagnosis within 3 months of HIV diagnosis, suggesting late presentation of these cases.

30. *Pneumocystis jiroveci* pneumonia (previously known as *Pneumocystis carini*) was the commonest ADI in Hong Kong in 2018, which accounted for 50.4% (70 cases). This proportion has increased comparing to that in 2017 (48.4%). The second most common primary ADI reported in 2018 was *Mycobacterium tuberculosis* which accounted for 15.8% of the reported AIDS cases (22 cases). They were followed by others (10.8%), other fungal infections (10.1%) and *Cytomegalovirus* diseases (8.6%). (Box 2.8) The universal voluntary testing has replaced unlinked anonymous screening at TB & Chest Clinics since 2009 in informing the HIV prevalence among TB patients. In 2018, the HIV testing coverage in patients attending government TB & Chest Clinic was 93.7% and HIV prevalence was 0.685%, which had remained at a low level of around 1% in the past few years. (Box 3.6)

### The median CD4 of newly reported HIV cases was lower in older patients

31. The median CD4 of newly reported HIV cases at the time of diagnosis in 2018 was 263/ul, which was similar to previous few years. The proportion with CD4>=200/ul in 2018 was 60.8%, which was also comparable to those in previous few years. Reporting of CD4 level has become a routine practice among doctors, providing useful information on the timing of diagnosis in the course of HIV infection. In 2018, 78% of HIV cases had their CD4 level at diagnosis reported, which was also comparable to those in the past few years. (Box 1.8) The median CD4 for those younger than 55 was 276/ul in 2018, which has decreased as compared to 302/ul in 2017. In addition, the median CD4 count among those who are aged 55 or above has decreased from 177.5/ul in 2017 to 168.5/ul in 2017. It was lower than that in the younger group, suggesting that older patients were diagnosed at a relatively late disease stage. (Box 1.9) As compared to the new cases acquired via homosexual/bisexual route, cases of heterosexual route were generally diagnosed at a later stage as evident by a smaller percentage of having positive laboratory test for specimens at diagnosis (positive BED IgG Capture Enzyme Immunoassay, i.e. BED assay or PCR) or having a negative HIV antibody test within 1 year. (Box 1.10)

Box 1.8 – Reported CD4 levels at HIV diagnosis


Year	No. of HIV reports	No. of	CD4 reports (%)	Median CD4 (cell/ul)		4>=200 I/ul) (%)
2009	396	291	(73.5%)	278	182	(62.5%)
2010	389	292	(75.1%)	207.5	149	(51.0%)
2011	438	324	(74.0%)	253.5	190	(58.6%)
2012	513	388	(75.6%)	279	251	(64.7%)
2013	559	448	(80.1%)	284	287	(64.1%)
2014	651	522	(80.2%)	319.5	374	(71.6%)
2015	725	598	(82.5%)	298	414	(69.2%)
2016	692	557	(80.5%)	284	371	(66.6%)
2017	681	570	(83.7%)	286	370	(64.9%)
2018	624	487	(78.0%)	263	296	(60.8%)

Box 1.9 - CD4 Reports by age group\*

J <u>A 1.7 -</u>	CD4 K	eports by age	group			
Age	Year	No. of HIV reports	No. of (%)	CD4 reports	Median CD4 (cell/ul)	% of CD4 >= 200 (cell/ul)
	2009	357	262	(73.4%)	296.5	(66.4%)
	2010	353	260	(73.7%)	215.5	(52.3%)
	2011	384	287	(74.7%)	275	(61.3%)
	2012	463	347	(74.9%)	300	(66.6%)
<55	2013	501	397	(79.2%)	308	(68.3%)
	2014	596	483	(81.0%)	330	(74.7%)
	2015	675	556	(82.4%)	306.5	(71.8%)
	2016	615	507	(82.4%)	296	(69.2%)
	2017	614	520	(84.7%)	302	(66.9%)
	2018	538	431	(80.1%)	276	(63.1%)
	2009	38	29	(76.3%)	72	(27.6%)
	2010	36	32	(88.9%)	121	(40.6%)
	2011	53	37	(69.8%)	126	(37.8%)
	2012	48	41	(85.4%)	193	(48.8%)
>=55	2013	58	51	(87.9%)	104	(31.4%)
	2014	53	39	(73.6%)	61	(33.3%)
	2015	48	42	(87.5%)	127	(35.7%)
	2016	68	50	(73.5%)	109	(40.0%)
	2017	61	50	(82.0%)	177.5	(44.0%)
	2018	81	56	(69.1%)	168.5	(42.9%)

<sup>\*:</sup> there may be a slight discrepancy between the sum of individual reports in Box 1.9 and the figures showed in Box 1.8 because of unknown age.

Box 1.10 - Recent HIV infections by route of transmission (2013-2018)



# The two commonest HIV-1 subtypes were CRF01 AE and B, but genetic diversity continued to increase. The level of drug resistance mutation remained low.

- 32. In 2018, about 86% of HIV reports had their subtypes documented, at a comparable level as in the past years. (Box 6.1) Subtypes CRF01\_AE and B remained the first and second most common subtypes identified among HIV type 1 or PCR positive case in Hong Kong, contributing to 42% and 32% of all cases with identified subtype from 2001 to 2018 respectively. In 2018, they together accounted for 69% of all HIV cases with subtype documented. (Box 6.2) Over the past decade, CRF\_01AE was found to be common in female, Asian non-Chinese, MSM and heterosexuals. (Box 6.4) On the other hand, subtype B was consistently commoner in male and MSM. In 2018, subtype B was found to be most common in Caucasian among all ethnicities, reversing the previous trend. (Box 6.5) Subtype C was commoner in female, Asian non-Chinese and heterosexual over the past decade. In particular, all IDU cases in 2018 were found to have subtype C (Box 6.6). Over the past few years, the proportion of both subtype CRF01\_AE and B showed a general decreasing trend, but with a rebound of subtype CRF01\_AE in 2018. In contrast, a trend of increasing diversity in other subtypes and circulating recombinant forms was noted, in particular since 2009. (Box 6.3) Notably, the proportion of subtype CRF07\_BC has increased from 4.6% in 2009 to 9.3% in 2018 while that subtype CRF08\_BC increased from 1.7% to 7.8% respectively.
- 33. According to the HIV resistance threshold survey conducted since 2003, the prevalence of intermediate or high level drug resistance related mutations in 2017 was 4.5%. This has ranged from 0% in 2006 to 5.4% in 2016 (Box 6.7). Among those patients with transmitted resistance, resistance to non-nucleoside reverse transcriptase inhibitors (NNRTI) was most common.

#### Discussion

- 34. After a modest drop in 2009 and 2010, a rising trend of HIV reports has been noted since 2011. Nevertheless, the total number of HIV reports in 2018 was 624, which had decreased by 8.4% as compared to the 681 cases in 2017. The decrease in the number of MSM cases was the major contributing factor for the decrease in the total number of HIV infection reported in 2018. The number of heterosexual transmission cases remained relatively stable and the number of cases among PWID also remained at a relatively low level of 1-15 cases per year in the last decade.
- 35. Although the number of HIV reports involving **homosexual/bisexual transmission (MSM)** has decreased, it continued to remain high and accounted for the largest proportion of cases with defined risks in 2018 (71.7%). From the data of previous few years, this high level of infection will likely continue in the foreseeable future and play a significant role in the local epidemic. Using the reconstruction methodology described in paragraphs 25 to 27 above, we can readily observe the predominance of infection among MSM. PRiSM 2017 showed an HIV prevalence of 6.54%, which was higher than the findings from previous rounds of PRiSM (2011) and HARIS (2014). Notwithstanding methodological differences between surveys, these figures highlight the existence of a concentrated HIV epidemic among gay and bisexual men in Hong Kong. Although the majority of the MSM cases (76.3%) were infected locally in

2018, the additional risk of HIV acquired from neighboring cities and regions should not be taken lightly due to the high level of international travel and cross-border sexual activities in the population. A decreasing median age of MSM cases was also noted (32 in 2018; 36 in 2008), signifying the importance of HIV prevention and publicity targeting the young population.


- 36. **Heterosexual transmission** remained relatively stable over the past few years and its proportion among the yearly new HIV infections has shown a general downward trend (33% in 2008; 23.1% in 2018) in tandem with the increasing proportion of MSM. In 2018, the proportion of female fell slightly from 51.2% in 2017 to 48.6. The HIV prevalence in Social Hygiene Clinic attendees and antenatal women remained at a relatively low level in the past decade and was 0.38% and 0.01% in 2018 respectively. However, consistent condom use rates of commercial / casual sex especially gauged from the surveys of heterosexual male remained far from satisfactory and could pose a threat of rebound in the number of cases infected via the heterosexual route.
- 37. The number of cases acquiring HIV via **drug injection** has remained stable. Despite that, the proportion of injection and risky needle-sharing behaviour among drug users as gauged from several surveys remained at a high level, which continued to pose a potential risk of cluster outbreak and rapid upsurge of infection in the population. Moreover, the HIV testing coverage in methadone clinics showed a decreasing trend in the past few years, which may miss or delay diagnosis and subsequent care of infected PWID. Remedial strategies to enhance HIV testing are underway, which will be evaluated periodically.
- 38. In conclusion, despite an 8% drop in 2018, the number of newly reported HIV infections in Hong Kong remained at a high level. Similar to the situation in many developed countries and neighboring areas, MSM infection continued to dominate the HIV epidemic in Hong Kong. The situation of heterosexual population and PWID population has been relatively stable in recent few years. However, significant levels of risk behavior exist in the at risk populations. Apart from locally acquired infections, infections acquired outside Hong Kong could also play an important factor influencing the local HIV epidemiology. In 2018, the HIV prevalence among the general population in Hong Kong was estimated to remain at a low level of less than 0.1%. To combat the HIV epidemic, continuous and collaborative effort in HIV prevention is essential.
- 39. In line with the international recommendations, all patients diagnosed HIV positive will receive antiretroviral treatment irrespective of the stage of disease, with the goal of a sustained undetectable viral load. According to the latest HIV treatment cascade for Hong Kong (2017), 86.7% of cases diagnosed HIV positive were on sustained antiretroviral treatment (HAART) while 94.3% of them having their viral load suppressed to an undetectable level (defined as less than 200 copies per mL in the latest blood test).

2. TABULATED RESULTS OF HIV/AIDS REPO	DILLING
---------------------------------------	---------


### **System description**

 The HIV/AIDS reporting system is a case-based notification system conducted on a voluntary, anonymous and confidential basis since 1984, with input from physicians and laboratories.

### System layout




Box 2.1 Annual and cumulative reports of HIV/AIDS cases



### Box 2.2 Source of reporting of HIV/AIDS cases


### (a) Year 2018

### (i) HIV (ii) AIDS



### (b) Cumulative (1984 - 2018)

(i) HIV (ii) AIDS



### Box 2.3 Ethnicity & gender of reported HIV/AIDS cases

### (a) Year 2018

Ethnicity	HIV						AIDS						
	Male		Female		Total		Male		Female		Total		
Chinese	418	(78.9%)	32	(34.0%)	450	(72.1%)	94	(86.2%)	13	(43.3%)	107	(77.0%)	
Non-Chinese	81	(15.3%)	61	(64.9%)	142	(22.8%)	15	(13.8%)	17	(56.7%)	32	(23.0%)	
Asian	29	(5.5%)	41	(43.6%)	70	(11.2%)	12	(11.0%)	16	(53.3%)	28	(20.1%)	
White	25	(4.7%)	0	(0.0%)	25	(4.0%)	2	(1.8%)	0	(0.0%)	2	(1.4%)	
Black	4	(0.8%)	6	(6.4%)	10	(1.6%)	0	(0.0%)	1	(3.3%)	1	(0.7%)	
Others	23	(4.3%)	14	(14.9%)	37	(5.9%)	1	(0.9%)	0	(0.0%)	1	(0.7%)	
Unknown	31	(5.8%)	1	(1.1%)	32	(5.1%)	0	(0.0%)	0	(0.0%)	0	(0.0%)	
Total	530	(100.0%)	94	(100.0%)	624	(100.0%)	109	(100.0%)	30	(100.0%)	139	(100.0%)	

### (b) Cumulative (1984 - 2018)


Ethnicity			HIV				AIDS					
	Male		Female		Total		Male		Female		Total	
Chinese	6066	(76.4%)	668	(37.5%)	6734	(69.3%)	1374	(83.0%)	160	(47.1%)	1534	(76.9%)
Non-Chinese	1661	(20.9%)	1076	(60.5%)	2737	(28.2%)	282	(17.0%)	180	(52.9%)	462	(23.1%)
Asian	759	(9.6%)	613	(34.5%)	1372	(14.1%)	156	(9.4%)	159	(46.8%)	315	(15.8%)
White	555	(7.0%)	25	(1.4%)	580	(6.0%)	95	(5.7%)	3	(0.9%)	98	(4.9%)
Black	118	(1.5%)	117	(6.6%)	235	(2.4%)	25	(1.5%)	16	(4.7%)	41	(2.1%)
Others	229	(2.9%)	321	(18.0%)	550	(5.7%)	6	(0.4%)	2	(0.6%)	8	(0.4%)
Unknown	209	(2.6%)	35	(2.0%)	244	(2.5%)	0	(0.0%)	0	(0.0%)	0	(0.0%)
Total	7936	(100.0%)	1779	(100.0%)	9715	(100.0%)	1656	(100.0%)	340	(100.0%)	1996	(100.0%)

### Box 2.4 Age distribution of reported HIV/AIDS cases


### (a) Median age of reported HIV/AIDS cases

		HIV		AIDS			
Year	Median age	Inter quai	tile range	Median age	Inter qua	rtile range	
		25%	75%		25%	75%	
1997	35	29	42	37	32	48	
1998	34	29	40	39	32	47.5	
1999	35	29	43	40	34	51	
2000	35	29	43	40	33.5	49.5	
2001	34.5	29	42	38	30.75	46.25	
2002	36	30	44	41	34	48	
2003	36	31	45	39	35	49.25	
2004	36	30	44	42	35	51	
2005	36	30	44	40	33.75	47.25	
2006	34	28	42	38	31	47	
2007	34	29	41	41	34	50.5	
2008	36	29	45	41	34	54	
2009	36	29	44	41	34	51	
2010	36	30	44	42	37	53	
2011	37	30	47	41	34	48.75	
2012	36	29	44	42	36	49	
2013	36	29	44	43.5	36	49.25	
2014	34	26	43	47	38	54.5	
2015	34	27	43	41.5	33	52	
2016	35	28	46	44	35	52	
2017	35	27	44	41	35	49.5	
2018	36	28	46.5	43	35	52.5	
Cumulative (1984 – 2018)	35	28	44	41	34	50	


### (b) Age & gender of reported HIV cases (Year 2018)




### (c) Age & gender of reported AIDS cases (Year 2018)



### (d) Age & gender of reported HIV cases (cumulative, 1984 - 2018)



### (e) Age & gender of reported AIDS cases (cumulative, 1985 - 2018)



# (f) Adults & children with reported HIV/AIDS in 2018

Age		HIV			AIDS					
Age	Male	Female	Total	Male	Female	Total				
Adult	530	94	624	109	30	139				
Children (age <=13)	0	0	0	0	0	0				
Total	530	94	624	109	30	139				

# Box 2.5 Exposure category of reported HIV/AIDS case

# (a) Distribution of reported HIV cases by exposure category (1999 - 2018)


Year Exposure Category (%)	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	Cumulative (1984 - 2018)
Heterosexual	127	115	127	146	117	112	118	130	111	145	117	124	120	135	147	135	150	149	121	144	3230
	(60%)	(63%)	(60%)	(56%)	(51%)	(42%)	(38%)	(35%)	(27%)	(33%)	(30%)	(32%)	(27%)	(26%)	(26%)	(21%)	(21%)	(22%)	(18%)	(23%)	(33%)
Homosexual	34	23	37	48	46	63	87	111	162	140	166	146	185	248	284	383	414	396	382	314	3916
	(16%)	(13%)	(17%)	(18%)	(20%)	(24%)	(28%)	(30%)	(39%)	(32%)	(42%)	(38%)	(42%)	(48%)	(51%)	(59%)	(57%)	(57%)	(56%)	(50%)	(40%)
Bisexual	10 (5%)	7 (4%)	7 (3%)	9 (3%)	5 (2%)	6 (2%)	12 (4%)	15 (4%)	19 (5%)	18 (4%)	9 (2%)	24 (6%)	18 (4%)	17 (3%)	22 (4%)	24 (4%)	56 (8%)	50 (7%)	75 (11%)	58 (9%)	523 (5%)
People who inject drugs	6	10	11	10	11	25	31	58	44	42	15	17	14	7	7	6	15	6	6	3	361
	(3%)	(5%)	(5%)	(4%)	(5%)	(9%)	(10%)	(16%)	(11%)	(10%)	(4%)	(4%)	(3%)	(1%)	(1%)	(1%)	(2%)	(1%)	(1%)	(0%)	(4%)
Blood contact	2 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	4 (1%)	0 (0%)	2 (0%)	3 (1%)	1 (0%)	0 (0%)	2 (0%)	1 (0%)	1 (0%)	1 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	85 (1%)
Perinatal	4 (2%)	2 (1%)	2 (1%)	1 (0%)	0 (0%)	0 (0%)	2 (1%)	2 (1%)	1 (0%)	0 (0%)	3 (1%)	3 (1%)	0 (0%)	1 (0%)	1 (0%)	0 (0%)	2 (0%)	0 (0%)	3 (0%)	0 (0%)	33 (0%)
Undetermined	30	26	29	46	50	62	59	57	75	87	85	75	99	104	97	102	88	91	93	105	1567
	(14%)	(14%)	(14%)	(18%)	(22%)	(23%)	(19%)	(15%)	(18%)	(20%)	(21%)	(19%)	(23%)	(20%)	(17%)	(16%)	(12%)	(13%)	(14%)	(17%)	(16%)
Total	213	183	213	260	229	268	313	373	414	435	396	389	438	513	559	651	725	692	681	624	9715
	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)

# (b) Distribution of reported AIDS cases by exposure category (1999 - 2018)


Year Exposure Category (%)	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	Cumulative (1985 - 2018)
Heterosexual	44	56	49	38	46	35	38	31	40	52	35	36	31	39	31	53	46	49	27	51	1048
	(72%)	(84%)	(82%)	(72%)	(82%)	(71%)	(59%)	(42%)	(51%)	(54%)	(46%)	(46%)	(38%)	(45%)	(37%)	(49%)	(42%)	(44%)	(30%)	(37%)	(53%)
Homosexual	8	1	5	8	7	8	13	21	20	25	28	27	32	34	36	39	50	41	45	62	593
	(13%)	(1%)	(8%)	(15%)	(13%)	(16%)	(20%)	(29%)	(25%)	(26%)	(37%)	(34%)	(39%)	(40%)	(43%)	(36%)	(45%)	(37%)	(49%)	(45%)	(30%)
Bisexual	1 (2%)	1 (1%)	2 (3%)	2 (4%)	0 (0%)	0 (0%)	3 (5%)	3 (4%)	1 (1%)	3 (3%)	3 (4%)	5 (6%)	4 (5%)	4 (5%)	5 (6%)	6 (6%)	7 (6%)	14 (13%)	11 (12%)	17 (12%)	116 (6%)
People who inject drugs	1	2	1	1	0	3	1	11	9	9	2	3	5	2	4	2	2	1	2	1	67
	(2%)	(3%)	(2%)	(2%)	(0%)	(6%)	(2%)	(15%)	(11%)	(9%)	(3%)	(4%)	(6%)	(2%)	(5%)	(2%)	(2%)	(1%)	(2%)	(1%)	(3%)
Blood contact	2	1	0	0	1	0	1	0	1	2	0	0	0	0	0	0	0	0	1	0	25
	(3%)	(1%)	(0%)	(0%)	(2%)	(0%)	(2%)	(0%)	(1%)	(2%)	(0%)	(0%)	(0%)	(0%)	(0%)	(0%)	(0%)	(0%)	(1%)	(0%)	(1%)
Perinatal	1 (2%)	1 (1%)	1 (2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	1 (1%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	10 (1%)
Undetermined	4 (7%)	5 (7%)	2 (3%)	4 (8%)	2 (4%)	3 (6%)	8 (13%)	7 (10%)	8 (10%)	5 (5%)	7 (9%)	7 (9%)	10 (12%)	7 (8%)	7 (8%)	8 (7%)	4 (4%)	6 (5%)	5 (5%)	8 (6%)	137 (7%)
Total	61	67	60	53	56	49	64	73	79	96	76	79	82	86	84	108	110	111	91	139	1996
	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)

### Box 2.6 Reported HIV/AIDS cases in people who inject drugs (1999-2018)

# (a) Reported HIV-infected people who inject drugs - by gender




## (b) Reported AIDS case in people who inject drugs - by gender




### Box 2.7 Reported sexually acquired HIV/AIDS cases (1999–2018)

## (a) Yearly reports of sexually acquired HIV cases



## (b) Yearly reports of sexually acquired AIDS cases



# (c) Ratio of heterosexual vs. homosexual / bisexual men reported with HIV/AIDS

Year	HIV	AIDS
1999	2.0 : 1	4.2 : 1
2000	2.6 : 1	23.5 : 1
2001	1.9 : 1	5.3 : 1
2002	1.7 : 1	2.7 : 1
2003	1.6 : 1	4.9 : 1
2004	1.1 : 1	3.8 : 1
2005	0.8 : 1	1.8 : 1
2006	0.7 : 1	0.8 : 1
2007	0.4 : 1	1.5 : 1
2008	0.6 : 1	1.4 : 1
2009	0.4 : 1	0.8 : 1
2010	0.4 : 1	0.8 : 1
2011	0.3 : 1	0.4 : 1
2012	0.3 : 1	0.6 : 1
2013	0.2 : 1	0.4 : 1
2014	0.2 : 1	0.7 : 1
2015	0.2 : 1	0.5 : 1
2016	0.2 : 1	0.5 : 1
2017	0.1 : 1	0.3 : 1
2018	0.2 : 1	0.3 : 1
Cumulative (1984 – 2018)	0.5 : 1	1.0 : 1

Box 2.8 Profile of primary AIDS defining illnesses (ADI) (1999 - 2018)

Year A8DI (%)	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	Cumulative (1985 - 2018)
Pneumocystic	23	30	26	25	22	22	20	27	28	37	32	36	37	39	37	46	55	48	44	70	841
Pneumonia (PCP)	(38%)	(45%)	(43%)	(47%)	(39%)	(45%)	(31%)	(37%)	(35%)	(39%)	(42%)	(46%)	(45%)	(45%)	(44%)	(43%)	(50%)	(43%)	(48%)	(50%)	(42%)
Mycobacterium	13	19	17	9	15	13	25	26	32	32	24	20	22	15	17	27	17	17	17	22	476
Tuberculosis	(21%)	(28%)	(28%)	(17%)	(27%)	(27%)	(39%)	(36%)	(41%)	(33%)	(32%)	(25%)	(27%)	(17%)	(20%)	(25%)	(15%)	(15%)	(19%)	(16%)	(24%)
Other fungal infections	5	4	5	8	4	6	5	4	3	3	6	5	8	10	10	12	9	11	7	14	185
	(8%)	(6%)	(8%)	(15%)	(7%)	(12%)	(8%)	(5%)	(4%)	(3%)	(8%)	(6%)	(10%)	(12%)	(12%)	(11%)	(8%)	(10%)	(8%)	(10%)	(9%)
Penicilliosis	7	5	1	7	5	4	7	11	4	6	1	6	2	6	3	2	6	9	7	5	134
	(11%)	(7%)	(2%)	(13%)	(9%)	(8%)	(11%)	(15%)	(5%)	(6%)	(1%)	(8%)	(2%)	(7%)	(4%)	(2%)	(5%)	(8%)	(8%)	(4%)	(7%)
Cytomegalovirus diseases	2	3	2	0	3	1	2	3	4	6	3	3	5	4	4	4	7	5	8	12	102
	(3%)	(4%)	(3%)	(0%)	(5%)	(2%)	(3%)	(4%)	(5%)	(6%)	(4%)	(4%)	(6%)	(5%)	(5%)	(4%)	(6%)	(5%)	(9%)	(9%)	(5%)
Non-TB mycobacterial infections	5 (8%)	1 (1%)	5 (8%)	2 (4%)	1 (2%)	2 (4%)	0 (0%)	1 (1%)	0 (0%)	1 (1%)	2 (3%)	0 (0%)	0 (0%)	2 (2%)	0 (0%)	3 (3%)	2 (2%)	3 (3%)	0 (0%)	0 (0%)	38 (2%)
Kaposi's sarcoma	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (2%)	0 (0%)	1 (2%)	0 (0%)	1 (1%)	4 (4%)	2 (3%)	1 (1%)	2 (2%)	1 (1%)	7 (8%)	0 (0%)	1 (1%)	3 (3%)	1 (1%)	1 (1%)	43 (2%)
Others	6	5	4	2	5	1	4	1	7	7	6	8	6	9	6	14	13	15	7	15	177
	(10%)	(7%)	(7%)	(4%)	(9%)	(2%)	(6%)	(1%)	(9%)	(7%)	(8%)	(10%)	(7%)	(10%)	(7%)	(13%)	(12%)	(14%)	(8%)	(11%)	(9%)
Total	61	67	60	53	56	49	64	73	79	96	76	79	82	86	84	108	110	111	91	139	1996
	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)

_	_	_		_
~	T	D	-           /	ALENCE SURVEYS
~	I ADIII ATEM	DECLII TO M	. <b>HI</b> V DDEV	VI EKILE ZUDNEAG
	IADULATED	ひとうひとしう ひに	- I I I V PRFV/	ALFINGE DURVETS

## **System description**

 This is a collection of data from HIV prevalence studies and public service records that contribute to the understanding of the HIV situation in selected community groups or settings.

# System layout

Target population	Setting	System	Since	Sample size	Data available in 2018
(a) Community	with predisposing risk factor	ors			
STI patients	Social Hygiene Clinics	Voluntary testing offered to clients	1985	Around 25000 – 40000/year	Yes
Drug users (1)	Methadone Clinics	Universal HIV Antibody (Urine samples) Testing Programme	2003	Around 6000 – 9000/year	Yes
Drug users (2)	Inpatient drug treatmet centres / institution	Unlinked anonymous screening (Urine samples)	1998	Around 150 – 700/year	Yes
Men who have Sex with Men	AIDS Concern	Voluntary testing offered to MSM (rapid tests)	2000	Around 200 - 1500/year	Yes
(MSM)	HIV Prevalence and Risk behavioural Survey of Men who have sex with men in Hong Kong(PRiSM)	Unlinked anonymous screening (urine samples) Voluntary testing (urine samples)	2006, 2008, 2011, 2017 rounds	Around 800/study (2006, 2008, 2011) and around 2400 in 2017	No
Female Sex Worker (FSW)	Community Based Risk Behavioural and Seroprevalence Survey for Female Sex Workers in Hong Kong (CRiSP)	Unlinked anonymous screening (urine samples) Voluntary testing (urine samples)	2006 round 2008 round	Around 900/study	No
	HIV and AIDS Response Indicator Survey (HARIS)	Voluntary testing (urine samples)	2013	Around 600/study for MSM	No
(b) Community	without known risk factors			•	
Blood donors	Hong Kong Red Cross Blood Transfusion Service	A requirement for all potential donors	1985	Around 180000 – 240000/year	Yes
Antenatal women	All maternal and child health centres and public hospitals	Universal voluntary testing (blood samples)	Sept 2001	Around 40000 - 50000/year	Yes
(c) Community	with undefined risk				
TB patients	TB and Chest Clinics of the Department of Health	Voluntary testing (blood samples)	1993	Around 2000 – 4500/year	Yes
Prisoners	Penal institutions	Unlinked anonymous screening (blood / urine samples)	1992	Around 1500 – 2500/year	Yes

# Box 3.1 HIV prevalence in blood donors at Hong Kong Red Cross Blood Transfusion Service

# (a) HIV detection rate by number of donated blood units (2009 - 2018)

Year	Units of blood donated	No. of units anti-HIV+	Positive detection rate of donated units (%)	95% C.I. for prevalence (%)
2009	214,709	3	0.001	( 0.0003 - 0.0041 )
2010	224,483	4	0.002	( 0.0005 - 0.0046 )
2011	234,086	5	0.002	( 0.0007 - 0.0050 )
2012	241,804	8	0.003	( 0.0014 - 0.0065 )
2013	244,198	7	0.003	( 0.0012 - 0.0059 )
2014	250,959	11	0.004	( 0.0022 - 0.0078 )
2015	257,859	16	0.006	( 0.0035 - 0.0101 )
2016	254,850	7	0.003	( 0.0011 - 0.0057 )
2017	241,607	9	0.004	( 0.0017 - 0.0071 )
2018	225,583	5	0.002	( 0.0007 - 0.0052 )

# (b) HIV prevalence in new and repeat blood donors (2009 - 2018)

		New donor	S		R8epeat dor	nors
Year	No. of donors	No. of donors anti-HIV+	HIV positivity rate (%) (95% C.I. (%))	No. of donors	No. of donors anti-HIV+	HIV positivity rate (%) (95% C.I. (%))
2009	46,158	1	0.002 ( 0.0001 – 0.0121 )	168,551	2	0.001 ( 0.0001 – 0.0043 )
2010	41,980	2	0.005 ( 0.0006 – 0.0172 )	182,503	2	0.001 ( 0.0001 – 0.0040 )
2011	42,684	2	0.005 ( 0.0006 – 0.0169 )	191,402	3	0.002 ( 0.0003 – 0.0046 )
2012	42,083	3	0.007 ( 0.0015 – 0.0208 )	199,721	5	0.003 ( 0.0008 – 0.0058 )
2013	40,315	1	0.002 ( 0.0001 – 0.0138 )	203,883	6	0.003 ( 0.0011 – 0.0064 )
2014	38,175	5	0.013 ( 0.0043 – 0.0306 )	212,784	6	0.003 ( 0.0010 – 0.0061 )
2015	36,183	6	0.017 ( 0.0061 – 0.0361 )	221,676	10	0.005 ( 0.0022 – 0.0083 )
2016	35,851	3	0.008 ( 0.0017 – 0.0245 )	218,999	4	0.002 ( 0.0005 – 0.0047)
2017	32,919	4	0.012 ( 0.0033 – 0.0311 )	208,688	5	0.002 ( 0.0008 – 0.0056 )
2018	29,551	3	0.010 ( 0.0021 – 0.0297 )	196,032	2	0.001 (0.0001 – 0.0037 )

Box 3.2 HIV prevalence in clients attending Social Hygiene Services, from voluntary blood testing (2009 – 2018)

Year	No. of blood samples	No. of samples tested anti-HIV+	Prevalence (%)	95% C.I. for prevalence (%)
2009	29,152	50	0.172	( 0.127 - 0.226 )
2010	26,300	40	0.152	( 0.109 - 0.207 )
2011	25,599	44	0.172	( 0.125 - 0.231 )
2012	26,679	55	0.206	( 0.155 - 0.268 )
2013	26,470	90	0.340	( 0.273 - 0.418 )
2014	25,960	105	0.404	( 0.331 - 0.490 )
2015	26,117	119	0.456	( 0.377 - 0.545 )
2016	25,685	124	0.483	( 0.402 - 0.576 )
2017	27,476	118	0.429	( 0.355 - 0.514 )
2018	25,560	97	0.379	( 0.308 - 0.463 )

Box 3.3 HIV prevalence in drug users attending methadone clinics

Year	No. of urine samples	No. of samples tested anti-HIV+	Prevalence (%)	95	5% C.I. for	preva	alence (%	)
2009*	7,765	38	0.489	(	0.346	-	0.672	)
2010*	7,445	36	0.484	(	0.339	-	0.669	)
2011*	6,960	37	0.53	(	0.374	-	0.733	)
2012*	6,742	42	0.62	(	0.449	-	0.842	)
Year	Total no. of methadone clinic attendees tested for HIV	Total no. of methadone clinic attendees tested positive for HIV	Prevalence (%)	95	% C.I. for	preva	alence (%	)
2013**	6,925	47	0.68	(	0.499	-	0.903	)
2014**	6,527	53	0.81	(	0.608	-	1.062	)
2015**	6,056	61	1.01	(	0.770	-	1.294	)
2016**	5,066	57	1.13	(	0.852	-	1.458	)
2017**	4,913	41	0.83	(	0.599	-	1.132	)
2018**	4,730	43	0.91	(	0.658	-	1.225	)

<sup>\*</sup>From the Universal HIV Antibody (Urine) Testing Programme in Methadone clinics.

<sup>\*\*</sup>Overall figures from all methadone clinic attendees.

Box 3.4 HIV prevalence in drug users attending inpatient drug treatment centres / institutions, from unlinked anonymous screening (2009 - 2018)

Year	No. of urine samples	No. of samples tested anti-HIV+	Prevalence (%)	(	95% C.I. f	or prev	valence (%	)
2009	430	3	0.698	(	0.144	-	2.039	)
2010	165	0	0	(		-		)
2011	396	1	0.253	(	0.006	-	1.407	)
2012	205	2	0.976	(	0.118	-	3.524	)
2013	188	0	0	(		-		)
2014	365	1	0.274	(	0.007	-	1.526	)
2015	335	3	0.896	(	0.185	-	2.617	)
2016	321	2	0.623	(	0.075	-	2.251	)
2017	295	5	1.695	(	0.550	-	3.955	)
2018	262	1	0.382	(	0.010	-	2.127	)

<sup>\*</sup> Unlinked anonymous screening was not performed in 2004.

Box 3.5 HIV prevalence in newly admitted prisoners from unlinked anonymous screening (2009 - 2018)

Year	No. of Samples	No. of samples tested anti-HIV+	Prevalence (%)	95% C.I. for prevalence (%)				
2009	1,929	15	0.778	(	0.435	-	1.283	)
2010	1,450	14	0.966	(	0.528	-	1.620	)
2011	1,445	27	1.869	(	1.231	-	2.718	)
2012	1,493	11	0.737	(	0.368	-	1.318	)
2013	1,460	14	0.959	(	0.524	-	1.609	)
2014	1,344	14	1.042	(	0.569	-	1.748	)
2015	1,453	18	1.239	(	0.734	-	1.958	)
2016	1,384	13	0.939	(	0.500	-	1.606	)
2017	1,229	9	0.732	(	0.335	-	1.390	)
2018	1,266	13	1.027	(	0.547	-	1.756	)

Box 3.6 HIV prevalence in patients attending government TB & Chest Clinics, from voluntary blood testing (2009 - 2018)

Voor	No. of blood complex	Coverage*		No of opti IIIV	Dravalance (0/)	95% C.I. for prevalence (%)				
Year	No. of blood samples	А	В	No. of anti-HIV+	Prevalence (%)	95% C.I. I	or prev	alence (%	,	
2009	3,993	89.0%	76.9%	40	1.002	( 0.716	-	1.364	)	
2010	3,833	90.2%	75.3%	28	0.730	( 0.485	-	1.056	)	
2011	3,656	90.6%	76.3%	33	0.903	( 0.621	-	1.268	)	
2012	3,707	91.2%	76.3%	22	0.593	( 0.372	-	0.899	)	
2013	3,536	88.2%	75.8%	24	0.679	( 0.435	-	1.010	)	
2014	3,345	88.1%	71.1%	23	0.688	( 0.436	-	1.032	)	
2015	3,291	91.1%	74.5%	24	0.729	( 0.467	-	1.085	)	
2016	3,272	92.0%	75.3%	28	0.856	( 0.569	-	1.237	)	
2017	3,256	93.9%	76.6%	31	0.952	( 0.647	-	1.351	)	
2018	3,359	93.7%	77.6%**	23	0.685	( 0.434	-	1.027	)	

<sup>\*</sup> coverage

A is the proportion of attendees of the government TB & Chest Cl8inics who have been tested for HIV in TB & Chest Clinics;

B is the proportion of total TB notifications from all sources, and the notified cases have been tested for HIV at government TB & Chest Clinics.

<sup>\*\*</sup> provisional figure

Box 3.7 HIV prevalence among antenatal women from Universal Antenatal HIV Antibody Testing Programme (2009 - 2018)

Year	Number of blood samples	Coverage*	Number ofpositive tests	Prevalence (%)	95% C.I. for prevalence (%)
2009	51,227	98.3%	7	0.01	( 0.0055 - 0.0282 )
2010	54,360	98.6%	10	0.02	( 0.0088 - 0.0338 )
2011	55,984	98.8%	6	0.01	( 0.0039 - 0.0233 )
2012	53,117	98.6%	9	0.02	( 0.0077 - 0.0322 )
2013	48,871	98.5%	7	0.01	( 0.0058 - 0.0295 )
2014	51,263	98.3%	2	0.004	( 0.0005 - 0.0141 )
2015	51,338	98.5%	5	0.01	( 0.0032 - 0.0227 )
2016	51,519	100.0%	9	0.02	( 0.0080 - 0.0332 )
2017	48,500	100.0%	7	0.01	( 0.0058 - 0.0297 )
2018	45,530	100.0%	4	0.01	( 0.0024 - 0.0225 )

<sup>\*</sup> coverage is the proportion of women attending public antenatal services who have been tested for HIV.

Box 3.8 HIV prevalence among MSM tested by AIDS Concern (2009 - 2018)

Year	Number of test*	Number of positive tests	Prevalence (%)	95% C.I. for prevalence (%)
2009	909	18	1.98	( 1.174 - 3.130 )
2010	854	18	2.11	( 1.249 - 3.331 )
2011	1,026	20	1.95	( 1.191 - 3.011 )
2012	1,492	30	2.01	( 1.357 - 2.871 )
2013	1,438	26	1.81	( 1.181 - 2.649 )
2014	2,054	42	2.04	( 1.474 - 2.764 )
2015	2,561	66	2.58	( 1.993 - 3.279 )
2016	3,481	78	2.24	( 1.771 - 2.796 )
2017	4,081	75	1.84	( 1.446 - 2.304 )
2018	3,661	47	1.28	( 0.943 - 1.707 )

<sup>\*</sup> HIV rapid test

Box 3.9 HIV prevalence among MSM – PRiSM\* (2006, 2008, 2011 and 2017), HARIS \*\*(2014)

Year	Number of urine specimen collected	Number of positive tests	Crude Prevalence (%)	Adjusted Prevalence (%)	95% C.I. for adjusted prevalence (%)			
2006	859	37	4.31	4.05	( 3.03 - 5.94 )			
2008	833	37	4.44	4.31	( 2.95 - 5.67 )			
2011	816	30	3.68	4.08	( 3.44 - 4.85 )			
2017	2427	86	3.54	6.54^	( 5.66 - 7.42 )			
Year	Number of urine specimen collected	Number of positive tests	Prevalence (%)	95% C.I. for prevalence (%)				
2014	564	33	5.85	(	4.2 - 8.1 )			

<sup>\*</sup>PRISM: HIV Prevalence and Risk behavioural Survey of Men who have sex with men in Hong Kong, a venue based survey including bars and saunas both in 2006 and 2008 round. Beaches was also added in 2011 round.

<sup>^</sup> PRiSM 2017: The HIV prevalence was estimated by addition of the self-reported HIV-positive (n=136) and projected positive cases among non-HIV-positive (by the positive test rate for HIV among non-HIV-positive) divided by the total number of sexually active MSM

<sup>\*\*</sup>HARIS: HIV and AIDS Response Indicator Survey for Men who have sex with men, a combined venue-based, non-governmental organisations centre-based and internet-based survey.

Box 3.10 HIV prevalence among Female Sex Workers – CRiSP\* (2006 and 2009), HARIS \*\*(2013)

Year	Number of urine specimen collected	Number of positive tests	Adjusted Prevalence (%)
2006	996	5	0.19
2009	986	2	0.05
2013	605	0	0.00

<sup>\*</sup>CRiSP: Community Based Risk Behavioural and Seroprevalence Survey for Female Sex Workers in Hong Kong, a venue based survey including one woman brothels, bars, night clubs, sauna, karaokes etc in 2006 and 2009 round.

<sup>\*\*</sup>HARIS: HIV and AIDS Response Indicator Survey for Female Sex Workers, a combined venue-based, non-governmental organisations centre-based and internet-based survey.

# 4. TABULATED RESULTS OF STATISTICS ON SEXUALLY TRANSMITTED INFECTIONS (STI)

#### System description

 This is a clinic based disease reporting system contributed by Social Hygiene Service, Department of Health. Summary tables are submitted quarterly by Social Hygiene Service. The clinics included in this surveillance system are: Chai Wan, Lek Yuen<sup>1</sup>, Wan Chai, Western<sup>2</sup>, Yau Ma Tei, South Kwai Chung<sup>3</sup>, Yung Fung Shee, Tuen Mun, Fanling ITC<sup>4</sup>, Tai Po, and Shek Wu Hui<sup>5</sup>.

<sup>&</sup>lt;sup>1</sup>Lek Yuen Clinic was closed in April 2005.

<sup>&</sup>lt;sup>2</sup>Western Social Hygiene Clinic was merged with Wan Chai Social Hygiene Clinic and Sai Ying Pun Dermatology Clinic wef 2.7.2003.

<sup>&</sup>lt;sup>3</sup>South Kwai Chung Clinic was closed on 27.3.2004.

<sup>&</sup>lt;sup>4</sup>Venereal Diseases Clinics in Fanling ITC was commenced operation in part-time basis on 1.9.2003 by appointment only.

<sup>&</sup>lt;sup>5</sup>Tai Po and Shek Wu Hui clinics were closed since 2001.


## Box 4.1 Total number of STI newly reported by individual Social Hygiene Clinic

### (a) Year 2018


	Chai Wan	Wan Chai	Yau Ma Tei	Yung Fung Shee	Tuen Mun	Fanling ITC#	Total
Male	187	1,886	3,447	737	537	673	7,467
Female	108	904	2,132	302	350	404	4,200
Total	295	2,790	5,579	1,039	887	1,077	11,667

<sup>#</sup> Venereal Diseases Clinics in Fanling ITC commenced operation in part-time basis on 1.9.2003 by appointment only.

### (b) 2014 - 2018



Box 4.2 Annual newly reported STIs in Social Hygiene Clinics




<sup>^</sup> NSGI / NGU : Non-specific Genital Infection / Non-gonococcal Urethritis

Box 4.3 Syphilis newly reported by Social Hygiene Clinics (2014 - 2018)


Year	2014	2015	2016	2017	2018
Syphilis					
Primary	41	53	40	69	50
Secondary	173	179	147	170	190
Early latent	108	130	170	178	289
Late latent	749	738	652	690	559
L8ate (cardiovascular / neuro)	7	4	7	6	7
Congenital (early)	0	0	0	0	0
Congenital (late)	4	3	4	3	0
Total	1,082	1,107	1,020	1,116	1,095

Box 4.4 Sexually acquired HIV infection in Hong Kong (1999-2018)



<sup>\*</sup> SHS: Social Hygiene Service

Box 4.5 Syndromic presentations of STI from Behavioural Survey of Social Hygiene Service (2014-2018)



5	TARUI ATED	RESULTS OF	N BEHAVIOURAL	MONITORING

# **System description**

• This is a tabulation of HIV risky behavioural data collected from different sources in Hong Kong.

# System layout

Source	Sexual behaviour	Drug-taking behaviour	Data available in 2018
AIDS Counselling and Testing Service (ACTS), Special Preventive Programme, CHP, DH	<ul> <li>Median no. of sexpartners in heterosexual men/MSM</li> <li>Recent history of commercial sex in heterosexual men</li> <li>Condom use in heterosexual men/MSM</li> </ul>		Yes
Social Hygiene Service (SHS)	<ul><li>Recent history of commercial sex / casual sex</li><li>Condom use in heterosexual men</li></ul>		Yes
Methadone clinics (DRS-M)		<ul><li>Proportion of current injectors</li><li>Practice of current needle- sharing</li></ul>	Yes
Shek Kwu Chau (SKC) Treatment and Rehabilitation Centre (DRS-S)		<ul><li>Proportion of current injectors</li><li>Practice of current needle- sharing</li></ul>	Yes
Central Registry of Drug Abuse (CRDA)		<ul> <li>Proportion of current injectors in all drug users</li> <li>Proportion of current injectors in new drug users</li> </ul>	Yes
Street Addict Survey (SAS) (From the Society for the Aid and Rehabilitation of Drug Abusers)		<ul><li>Proportion of current injectors</li><li>Practice of current needle- sharing</li></ul>	Yes
AIDS Concern testing service for MSM (AC)	- Condom use in MSM		Yes
HIV Prevalence and Risk behavioural Survey of Men who have sex with men in Hong Kong (PRiSM)	- Condom use in MSM		No
HIV and AIDS Response Indicator Survey (HARIS)	- Condom use in MSM		Yes

Box 5.1 Median number of sex partners in the previous year among adult heterosexual men / MSM attending AIDS Counselling and Testing Service (ACTS) (2009-2018)


	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018
Heterosexual men - Regular sex partners*	1	1	1	1	1	1	1	1	1	1
Heterosexual men - Commercial sex partners**	3	3	2	3	2	3	2	2	2	2
Heterosexual men - Casual sex partners***	1	1	1	1	1	1	1	1	1	1
MSM - Regular sex partners*	1	1	1	1	1	1	1	1	1	1
MSM - Commercial sex partners**	3	1.5	1	2	4.5	5	2	1	2	2
MSM - Casual sex partners***	4	3.5	3	3	3	4	4	3	4	3


<sup>^</sup> Adult: aged 18 or above.

<sup>\*</sup> Regular sex partners used to refer to long-term sex partners including spouse, mistress, and steady boyfriends / girlfriends for at least one year, or if less than one year, one with whom is expected to continue sexual relationship. This definition of regular sex partners in 2008 has been further refined to include (other than the long-term sex partners) sex buddy that refers to regular sex only partner for at least 6 months, or if less than 6 months, one with whom is expected to continue sexual relationship.

<sup>\*\*</sup> Commercial sex partners are defined as those who have sexual intercourse in exchange for money, goods or services. Examples are prostitutes and customers of prostitutes.

<sup>\*\*\*</sup> Casual sex partners, the two do not have steady relationship.





<sup>\*</sup> Commercial sex partners are defined as those who have sexual intercourse in exchange for money, goods or services. Examples are female sex workers and their clients. Casual sex partners are defined as those who are non-regular and non-commercial. Examples are those on one-night stand. SHS & ACTS refers to such history in past one year.


^ Adult: aged 18 or above.

Remarks: SHS – Social Hygiene Services

ACTS - AIDS Counselling and Testing Service

#### Box 5.3 Condom use with regular partners among adult heterosexual men

#### (a) Consistent condom use\* with regular partners\*\* among adult^ heterosexual men (2009-2018)




- \* Consistent condom use is defined as always or 100% of the time using a condom.

  ACTS captures such condom usage in past one year while SHS captures such usage in past 3 months.
- \*\* Regular sex partners used to refer to long-term sex partners including spouse, mistress, and steady girl friends for at least one year, or if less than one year, one with whom is expected to continue sexual relationship. This definition of regular sex partners in 2008 has been further refined to include (other than the long-term sex partners) sex buddy that refers to regular sex only partner for at least 6 months, or if less than 6 months, one with whom is expected to continue sexual relationship.
- ^ Adult: aged 18 or above.

Remarks: SHS - Social Hygiene Services, ACTS - AIDS Counselling and Testing Service

#### (b) Condom use for last sex with regular partners\* among adult^ heterosexual men (2009-2018)




- Regular sex partners used to refer to long-term sex partners including spouse, mistress, and steady girl friends for at least one year, or if less than one year, one with whom is expected to continue sexual relationship. This definition of regular sex partners in 2008 has been futher refined to include (other than the long-term sex partners) sex buddy that refers to regular sex only partner for at least 6 months, or if less than 6 months, one with whom is expected to continue sexual relationship.
- ^ Adult: aged 18 or above.

Remarks: SHS – Social Hygiene Services

ACTS - AIDS Counselling and Testing Service

Box 5.4 Condom use with commercial / casual partners among adult heterosexual men

#### (a) Consistent condom use\* with commercial / casual partners\*\* among adult^ heterosexual men (2009-2018)




- \* Consistent condom use is defined as always or 100% of the time using a condom for vaginal or anal sex in past 1 year. ACTS captures such condom usage in past one year while SHS captures such usage in past 3 months.
- \*\* Commercial sex partners are defined as those who have sexual intercourse in exchange for money, goods or services. Examples are female sex workers and their clients. Casual sex partners are defined as those who are non-regular and non-commercial. Examples are those on one-night stand.
- ^ Adult: aged 18 or above.

Remarks: SHS – Social Hygiene Services

ACTS - AIDS Counselling and Testing Service

#### (b) Condom use for last sex\* with commercial / casual partners\*\* among adult^ heterosexual men (2009-2018)




- \* ACTS defined "condom use for last sex" as using a condom for the last (vaginal and/or anal and/or oral-genital) sex within the past 1 year.
- \*\* Commercial sex partners are defined as those who have sexual intercourse in exchange for money, goods or services. Examples are female sex workers and their clients. Casual sex partners are defined as those who are non-regular and non-commercial. Examples are those on one-night stand.
- ^ Adult: aged 18 or above.

Remarks: SHS – Social Hygiene Services, ACTS - AIDS Counselling and Testing Service

#### Box 5.5 Condom use among Men have Sex with Men (MSM)


#### (a) Consistent condom use\* among MSM (2009-2018)



- \* Consistent condom use is defined as always or 100% of the time using a condom. ACTS captures such condom usage in past one year while AC captures such usage in past 3 months.
- \*\* Regular sex partners used to refer to long-term sex partners including spouse, mistress, and steady boy / girl friends for at least one year, or if less than one year, one with whom is expected to continue sexual relationship. This definition of regular sex partners in 2008 has been futher refined to include (other than the long-term sex partners) sex buddy that refers to regular sex only partner for at least 6 months, or if less than 6 months, one with whom is expected to continue sexual relationship.
- \*\*\* Casual sex partners, the two do not have steady relationship.
- \*\*\*\* The data in 2012 only from January to March.
- # Since April 2012, the sex partner types from AC survey further breakdown into regular sex partner, causal sex partner and boyfriend.
- ^ Adult: aged 18 or above.

Remarks: ACTS - AIDS Counselling and Testing Service, AC - AIDS Concern, PRiSM- HIV Prevalence and Risk Behavioural Survey of MSM in Hong Kong

#### (b) Condom use for last anal sex among MSM (2009-2018)




<sup>\*</sup> Regular sex partners used to refer to long-term sex partners including spouse, and steady boy friends for at least one year, or if less than one year, one with whom is expected to continue sexual relationship. This definition of regular sex partners in 2008 has been futher refined to include (other than the long-term sex partners) sex buddy that refers to regular sex only partner for at least 6 months, or if less than 6 months, one with whom is expected to continue sexual relationship.

- \*\* Casual sex partners, the two do not have steady relationship.
- \*\*\* The data in 2012 only from January to March.
- ^ Adult: aged 18 or above.
- # Since April 2012, the sex partner types from AC survey further breakdown into regular sex partner, causal sex partner and boyfriend.

Remarks: ACTS - AIDS Counselling and Testing Service

AC - AIDS Concern, HARiS - HIV and AIDS Response Indicator Survey





- \* Definitions differ for different data sources. DRS-S refers to drug injecting behaviour in past 6 months (before 2006, it referred to drug injecting at the time of programme admission); DRS-M refers to drug injecting at the time of programme admission; SAS refers to drug injecting behaviour in past 1 month (before 2007, it referred to drug injecting in past 3 months); CRDA refers to drug injecting behaviour in past 4 weeks.
- \*\* New clients refer to people who are known to the CRDA for the first time in a period. For a particular period, a person will be regarded as a newly reported person if and only if the person does not have any report before the specified period.


Remarks: DRS-S - Shek Kwu Chau Treatment and Rehabilitation Centre (Newly / Re-admitted case)

DRS-M - Methadone clinics (Newly admitted case only)

SAS - Street Addict Survey (From the Society for the Aid and Rehabilitation of Drug Abusers (SARDA))

CRDA - Central Registry of Drug Abuse

Box 5.7 Proportion of current needle-sharers\* (2009-2018)



\* This figure referred to the proportion of current syringe sharing behaviour among current injectors. Definitions differ for different data sources. DRS-S refers to such sharing behaviour among those who injected drug in past 6 months (before 2006, it referred to such sharing behaviour in past 6 months among those who injected drug at the time of programme admission); SAS refers to such sharing behaviour among those who injected drug in past 1 month (before 2007, it referred to such sharing behaviour in past 3 months); DRS-M refers to such sharing behaviour in past 4 weeks among those who injected drug at the time of programme admission.

Remarks: DRS-S - Shek Kwu Chau Treatment and Rehabilitation Centre (Newly / Re-admitted cases)

DRS-M - Methadone clinics (Newly admitted case only)


SAS - Street Addict Survey (From the Society for the Aid and Rehabilitation of Drug Abusers (SARDA))

#### 6. TABULATED RESULTS OF HIV-1 GENOTYPING STUDIES

#### **System description**

• This is a laboratory based reporting system contributed by Virology Division of Public Health Laboratory Services Branch, Centre for Health Protection, Department of Health. HIV viral isolates are collected from the confirmatory laboratories for subtype analysis which are collated with epidemiological information when available. Subtype results are submitted monthly by Virology Division. The confirmatory laboratories included in this surveillance system are: DH Public Health Laboratory Service Branch, Microbiology laboratories of Queen Elizabeth Hospital, Prince of Wales Hospital, Hong Kong Red Cross Blood Transfusion Service. Subtype analysis was commenced since 2001.

Box 6.1 Proportion of reports\* with subtypes by year in Hong Kong, 2001 - 2018




<sup>\*:</sup> including cases with HIV type 1 or PCR positive result.

### **Box 6.2 Distribution of HIV-1\* subtypes**

#### (i) Cumulative (2001-2018)


### (ii) Year 2018



<sup>\*:</sup> including cases with HIV type 1 or PCR positive result.

<sup>\*\*:</sup> including subtype A, A1, A2, B', D, F, F1, G, CRF03\_AB, CRF05\_DF, CRF06\_CPX, CRF09\_cpx, CRF10\_CD, CRF11\_CPX, CRF12\_BF, CRF13\_cpx, CRF14\_BG, CRF15\_01B, CRF55\_01B.


Box 6.3 Trend in the common HIV-1\* subtypes in Hong Kong, 2001 – 2018



<sup>\*:</sup> including cases with HIV type 1 or PCR positive result.


Box 6.4 Trend in HIV-1\* subtype CRF01\_AE in Hong Kong, 2001 - 2018

## (a) By gender (proportion of cases with subtype CRF01\_AE)




<sup>\*:</sup> including cases with HIV type 1 or PCR positive result.

# (b) By ethnicity (proportion of cases with subtype CRF01\_AE)




## (c) By route of transmission (proportion of cases with subtype CRF01\_AE)




Box 6.5 Trend in HIV-1\* subtype B in Hong Kong, 2001 - 2018

## (a) By gender (proportion of cases with subtype B)




<sup>\*:</sup> including cases with HIV type 1 or PCR positive result.

## (b) By ethnicity (proportion of cases with subtype B)




## (c) By route of transmission (proportion of cases with subtype B)




Box 6.6 Trend in HIV-1\* subtype C in Hong Kong, 2001 - 2018

# (a) By gender (proportion of cases with subtype C)




<sup>\*:</sup> including cases with HIV type 1 or PCR positive result.


## (b) By ethnicity (proportion of cases with subtype C)



# (c) By route of transmission (proportion of cases with subtype C)



Box 6.7 Prevalence of intermediate or high level drug resistance related mutation among newly diagnosed HIV patients, 2003-2017



### Appendix I: HIV/AIDS report form (DH2293)

#### DEPARTMENT OF HEALTH HIV/AIDS Report Form

The HIV/AIDS voluntary reporting system has been in place since 1984. All doctors are encouraged to report patients with HIV/AIDS and to update status of the previously reported cases where appropriate. This is an anonymous and confidential system. Data collected is crucial for understanding the HIV epidemiology in Hong Kong and is used in global analysis only. Aggregate statistics are released quarterly and can be obtained at www.aids.gov.hk. For any query, please call 3143 7225 or email us at aids@dh.gov.hk. Completed form can be faxed to 2297 3239 or mailed to Special Preventive Programme, Centre for Health Protection, Department of Health.

Please complete  $\underline{ALL}$  sections and ' $\checkmark$ ' in the appropriate box.

	Section (A) – Report of HIV							
All Sex :   M   F   For female, is she pregnant?   No   Yes   If Yes, go to Box I	[1] THIS is a NEW report or UPDATE of previous reported case							
5  Date of birth:	[2] Your reference code number <sup>vi</sup> : [3] Does the patient have a HK identity card? $\_$ Yes $\_$ No							
	[4] Sex : $\square$ M $\square$ F For female, is she pregnant? $\square$ No $\square$ Yes	If yes,	, go to Box 1					
Suspected risk(s) for HIV infection*	[5] Date of birth: / / (ddmmyyyy) O	R Age at last	birthday:					
Heterosexual   Homosexual   Bisexual     Injecting fung uses     Injecting f	[6] Ethnicity: Chinese Asian, specify: Caucasian	Black Oth	ers:			Unkno	wn	
Bax I	[7] Suspected risk(s) for HIV infection <sup>vii</sup>			-		<del></del>		
Gravida								
Obters, please specify:						/ / (11		
							(ddillillyyyy)	
Not asked   Si Suspected place of infection:   Hong Kong   Mainland China, specify:     Others, specify:     Asked, but undetermined   Not asked			Plan: TOP Continue pregnancy					
S   Suspected place of infection:   Hong Kong   Mainland China, specify:								
	<del>_</del>	Others, specify:						
9  Date of laboratory diagnosis in HK:					, ., .			
To   Confirmation test:   Yes   No			vy)					
11] Name of Laboratory:			<del></del>					
14  Any previous negative HIV test: No   Yes   If yes, date of last negative HIV test   / / (ddmmyyyy)     15  CD4 (cells/µl): Date: / / (ddmmyyyy)     16  HIV status of spouse/regular partner:   HIV positive   HIV negative   Unknown   No spouse/regular partner			_	ımber:				
15] CD4 (cells/μ1):   Date:	[13] Previous HIV diagnosis outside HK: No Yes If yes, date:		/ / (ddmmyyyy) place:					
Tell   HIV status of spouse/regular partner:	[14] Any previous negative HIV test: No Yes	If yes, date of l	last negative HIV test			/ / (dd	mmyyyy)	
Section (B) - Report of AIDS   Yes \ No (Go to Section C)	[15] CD4 (cells/µl): Date:	/ /	/ (ddmmyyyy)	-				
Tel:   Yes   No (Go to Section C)   Section C    Section C    No (Go to Section C)   Section C    Section C	[16] HIV status of spouse/regular partner:	e HIV negati	ive Unknown No	spouse/regula	ar partner			
The section (C) - Report of Outcome   Correspondence   Correspondence Address:   Correspondence   Correspondenc	Section (B) - Report of AIDS							
Date of diagnosis:	[17] Has the patient developed AIDS viii: Yes No (Go	to Section C)						
Date of diagnosis:	[18] If yes, the AIDS defining illness(es) is (are):							
Date of diagnosis:	(i) Date of diagnosis:				/	/ / (ddmmyyyy)		
Eaction (C) - Report of Outcome    Company	(ii)	Date of diagnosis: / / (ddmmyyyy					ууу)	
Section (C) – Report of Outcome  [20] Has the patient referred to/seen at public HIV clinic Yes No If yes, referred on/seen at:  [21] Has the patient defaulted follow up? Yes No If yes, last seen on: / / (ddmmyyyy)  [22] Is the patient under private HIV medical care Yes No  [23] Has the patient left HK? Yes No If yes, last seen on: / / (ddmmyyyy)  [24] Has the patient died? Yes No If yes, date of death: / / (ddmmyyyy) Cause:  Section (D) – Correspondence  Name of medical practitioner:	(iii)	Date of diagnosi			/	/ (ddmmy	ууу)	
[20] Has the patient referred to/seen at public HIV clinic Yes No If yes, referred on/seen at: // (ddmmyyyy)  [21] Has the patient defaulted follow up? Yes No If yes, last seen on: // (ddmmyyyy)  [22] Is the patient under private HIV medical care Yes No  [23] Has the patient left HK? Yes No If yes, last seen on: // (ddmmyyyy)  [24] Has the patient died? Yes No If yes, date of death: // (ddmmyyyy) Cause:  Section (D) - Correspondence  Name of medical practitioner:			Date:	_	/	/ (ddmmy	ууу)	
[20] Has the patient defaulted follow up?  [21] Has the patient defaulted follow up?  [22] Is the patient under private HIV medical care  [23] Has the patient left HK?  [24] Has the patient died?  [25] Is the patient died?  [26] If yes, last seen on:  [27] If yes, last seen on:  [28] Has the patient died?  [29] If yes, last seen on:  [20] If yes, last seen on:  [21] If yes, last seen on:  [22] If yes, last seen on:  [23] If yes, last seen on:  [24] If yes, last seen on:  [25] If yes, last seen on:  [26] If yes, last seen on:  [27] If yes, last seen on:  [28] If yes, last seen on:  [29] If yes, last seen on:  [20] If yes, last seen on:  [21] If yes, last seen on:  [22] If yes, last seen on:  [23] If yes, last seen on:  [24] If yes, last seen on:  [25] If yes, last seen on:  [26] If yes, last seen on:  [27] If yes, last seen on:  [28] If yes, last seen on:  [29] If yes, last seen on:  [20] If yes, last yes	Section (C) – Report of Outcome	TC	C 1 /					
[22] Is the patient under private HIV medical care  [23] Has the patient left HK?  [24] Has the patient died?  [25] Yes No  [26] If yes, last seen on:  [26] If yes, last seen on:  [26] If yes, last seen on:  [27] If yes, last seen on:  [28] If yes, last seen on:  [29] If yes, last seen on:  [29] If yes, last seen on:  [29] If yes, last seen on:  [20] If yes, last	[20] Has the patient referred to/seen at public HIV clinic Yes	LINO		/_/	(ddmmyyyy)			
[23] Has the patient left HK?	[21] Has the patient defaulted follow up?	□No If	yes, last seen on:	/ /	(ddmmyyyy)			
[24] Has the patient died?	[22] Is the patient under private HIV medical care Yes	□No						
Section (D) – Correspondence  Name of medical practitioner:	[23] Has the patient left HK?	□No If	yes, last seen on:	/ /	(ddmmyyyy)			
Name of medical practitioner:		of death:	/ /	(ddmmyyyy	) Cause:			
Correspondence Address:  Tel: Fax:	-							
Tel: Fax:				in priv	ate practice in	public service	e	
	· ————————————————————————————————————							
Email: Date: / / (ddmmyyyy)								
	Email:	Date:	/ / (ddmmyyyy	")				

vi Please put down any code of your choice (e.g. case number) for matching purpose only.

vii Please tick the most likely risk for contracting HIV infection. If there is more than 1 suspected risk, please put down 1 & 2 in descending order of the two most likely risks.

viii Surveillance definition of AIDS: a definitive laboratory diagnosis of HIV infection AND one or more of the AIDS indicator conditions (July 1995, Scientific Committee on AIDS. Available at www.aids.gov.hk/english/surveillance/definition.html).

Appendix II: Classification system for HIV infection and surveillance case definition for AIDS in adolescents and adults in Hong Kong.

## A definitive laboratory diagnosis of HIV infection normally by a positive screening test for HIV antibody (e.g. ELISA) supplemented by a confirmatory test (e.g. western blot)

# one or more of the AIDS indicator conditions

# AIDS indicator conditions

Candidiasis of bronchi, trachea, or lungs

Candidiasis, oesophageal

Cervical cancer, invasive

Coccidiodomycosis, disseminated or extrapulmonary

Cryptococcosis, extrapulmonary

Cryptosporidiosis, chronic intestinal (>1 month's duration)

Cytomegalovirus disease (other than liver, spleen or nodes)

Cytomegalovirus retinitis (with loss of vision)

Encephalopathy, HIV-related

Herpes simplex: chronic ulcer(s) (>1 month's duration); or bronchitis,

pneumonitis, or oesophagitis

Histoplasmosis, disseminated or extrapulmonary

Isosporiasis, chronic intestinal (>1 month's duration)

Kaposi's sarcoma

Lymphoma, Burkitt's (or equivalent term)

Lymphoma, primary, of brain

Mycobacterium tuberculosis; extrapulmonary or pulmonary/cervical

lymph node (only if CD4<200/ul)

Pneumonia, recurrent

Penicilliosis, disseminated

Mycobacterium, other species or unidentified species, disseminated or

extrapulmonary

Pneumocystis carinii pneumonia

Progressive multifocal leukoencephalopathy


Salmonella septicaemia, recurrent

Toxoplasmosis of brain

Wasting syndrome due to HIV

Hong Kong has adopted the 1993 Centers for Disease Control and Prevention (CDC) AIDS classification with 3 modifications: (1) disseminated penicilliosis is added as one AIDS-defining condition, (2) pulmonary or cervical lymph node tuberculosis included only if CD4  $< 200 \,\mu$ l, (3) a CD4  $< 200 \,\mu$ l without any AIDS-defining condition is not counted as AIDS.

Appendix III: Condom distribution for the prevention of HIV and STI by Department of Health



#### Note:

- 1. Community network includes collaborative projects with Action for REACH OUT, AIDS Concern, CHOICE, Phoenix Project of SARDA, Gay Harmony and Midnight Blue.
- 2. SPP and others condom distribution points, including Travel Health Centres, Correctional Services Department, Tuberculosis and Chest Clinics, Elderly Health Centre, Professional Development and Quality Assurance Service.